Compare GSK plc (GSK) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Total World Stock Index Fund ETF — how do they compare? GSK plc trades at $46.65 (market cap $91.88B), while Vanguard Total World Stock Index Fund ETF trades at $159.63 (market cap $101.70B). The key difference: GSK plc and Vanguard Total World Stock Index Fund ETF are close in size by market cap, and GSK plc pays a 3.9% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| GSK | VT | |
|---|---|---|
Market Cap | $91.88B | $101.70B |
Volume | 7,730,529 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $162.39 |
52-Week Low | $43.24 | $134.19 |
Typical Hold Time | 93 Days | 53 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
VT, the Vanguard Total World Stock ETF, trades at $159.39, down 0.16% on the day. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The ETF offers broad global diversification with over 9,700 stocks and a low expense ratio of 0.06%, though key valuation ratios like P/E and P/B are not disclosed in the provided data. Recent news highlights its role as a core holding for long-term investors seeking worldwide exposure.
The outlook for VT is supported by its cost efficiency and diversification benefits, but near-term technical weakness and competitive pressures from lower-fee alternatives pose risks. Investor sentiment is mixed, with some analysts favoring VT for its comprehensive coverage, while others point to higher expenses relative to peers. Macroeconomic uncertainties and trade tensions could impact global equity returns, affecting VT's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
